Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
42.85
-0.05 (-0.12%)
Oct 30, 2025, 9:16 AM EDT - Market open
Crinetics Pharmaceuticals Revenue
Crinetics Pharmaceuticals had revenue of $1.03M in the quarter ending June 30, 2025, with 158.40% growth. This brings the company's revenue in the last twelve months to $1.39M, up 0.51% year-over-year. In the year 2024, Crinetics Pharmaceuticals had annual revenue of $1.04M, down -74.11%.
Revenue (ttm)
$1.39M
Revenue Growth
+0.51%
P/S Ratio
2,902.41
Revenue / Employee
$3,185
Employees
437
Market Cap
4.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.04M | -2.97M | -74.11% |
| Dec 31, 2023 | 4.01M | -724.00K | -15.28% |
| Dec 31, 2022 | 4.74M | 3.66M | 339.42% |
| Dec 31, 2021 | 1.08M | 1.01M | 1,418.31% |
| Dec 31, 2020 | 71.00K | -1.12M | -94.05% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CRNX News
- 7 days ago - Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting - GlobeNewsWire
- 19 days ago - Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 4 weeks ago - Crinetics: FDA Approval And Expansion Of Palsonify In Focus, Maintaining 'Buy' Rating - Seeking Alpha
- 4 weeks ago - Crinetics Pharmaceuticals, Inc. - Special Call - Seeking Alpha
- 4 weeks ago - Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly - GlobeNewsWire
- 7 weeks ago - Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) - GlobeNewsWire